Plasma IGF-I and IGF-binding protein 3 (IGFBP-3) were determined by radioimmunoassay in term infants (n = 51) at 0, 2,4, 6, and 12 mo and preterm infants (n = 51) at -3 (28.4 wk postconceptional age), -2, -1.5, -1,0,2,4,6,9, and 12 rna from expected term. The effects of gestational age at birth (term or preterm) and study age were determined by repeated measures analysis of variance and Fisher's least squares difference. In preterm infants, IGF-I increased between -3 and 2 mo from 0.75 to 10.4 nM, decreased between 2 and 9 mo to 7.3 nM, and increased again between 9 and 12 mo to 10.1 nM (p < 0.0001), whereas IGFBP-3 increased relatively little from -3 to 0 rna (14.2 to 30.2 nM, p < 0.05) and plateaued from 2 to 12 mo (49.8 to 62.3 nM). At 0 rna, IGF-I and IGFBP-3 were the same in term and preterm infants, but preterm infants had higher IGF-I from 2 IGF mediate the growth-promoting actions of growth hormone in regulating the proliferation and differentiation of different cell types (1). These polypeptides which are structurally homologous to insulin also exert insulin-like metabolic effects. Both these effects are mediated through target cell surface receptors (2). Most tissues in the body produce IGF, and they are present in serum mostly bound to specific high molecular weight binding proteins (3). Of the six IGFBP that have been identified so far, IGFBP-3 is the major form present in the serum (1, 2) and demonstrates a high affinity for both IGF-I and IGF-II. IGFBP-3 can exhibit either an inhibitory (4) or a potentiating (5) effect on IGF-I bioactivity in vitro, depending on its ability to alter the equilibrium between IGF-I and its receptor (5).
IGF mediate the growth-promoting actions of growth hormone in regulating the proliferation and differentiation of different cell types (1) . These polypeptides which are structurally homologous to insulin also exert insulin-like metabolic effects. Both these effects are mediated through target cell surface receptors (2) . Most tissues in the body produce IGF, and they are present in serum mostly bound to specific high molecular weight binding proteins (3) . Of the six IGFBP that have been identified so far, IGFBP-3 is the major form present in the serum (1, 2) and demonstrates a high affinity for both IGF-I and IGF-II. IGFBP-3 can exhibit either an inhibitory (4) or a potentiating (5) effect on IGF-I bioactivity in vitro, depending on its ability to alter the equilibrium between IGF-I and its receptor (5) . Although IGF-I is thought to play an important role in postnatal growth (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) , there is disagreement among authors (16) (17) (18) (19) about the effects of postnatal age on plasma IGF-I in early infancy. The usefulness of obtaining plasma IGF-I concentrations in infancy is limited because normal values for this age group have not been established. Data on the circulating IGF-I concentrations in healthy term infants in early infancy are available from only five published reports (10, (16) (17) (18) (19) . These studies were either cross-sectional (10, 16, 17) or followed a relatively small number of infants longitudinally (16) (17) (18) (19) . Plasma IGFBP-3 concentration during infancy has not been reported previously. The objectives of this study were to establish normative data on plasma IGF-I and IGFBP-3 throughout infancy in healthy infants born at term and to contrast these concentrations to those of appropriate-forgestational-age preterm infants selected from the same population.
METHODS
Subject enrollment. Healthy term infants were enrolled at birth and were followed at approximately bimonthly intervals 582 RAJARAM ET AL. from birth until 12 mo of age. Apropriate-for-gestational-age preterm infants (28.4 ± 1.5-wk PCA, mean ± SD) were enrolled after birth or -3 mo from expected term and followed longitudinally until 12 mo (this and all subsequent ages were corrected to expected term). Parental consent was obtained before enrollment according to a protocol approved by the Institutional Review Board of The University of Tennessee, Memphis. Both the term and the preterm infants were selected from the same hospital population. The neonatal and perinatal characteristics of the stud y infants are given in Table 1 .
Study design. Term and preterm infants were the subjects of separate but concurrent randomized trials to study the effects of long chain N-3 or N-6 fatty acids on development. Blood sampling. Blood was collected from term infants at birth (0 mo, 40 ± 1 wk PCA), 2 mo (48 ± 1 wk PCA), 4 mo (57 ± 1 wk PCA), 6 mo (66 ± 1 wk PCA), and 12 mo (92 ± 1 wk PCA). Blood was collected from preterm infants near birth, when they reached an enteral intake of ::::100 kcal/kg/d, and at biweekly intervals thereafter until discharge from the hospital: -3 mo (3-5 d of age , 28 ± 2 wk PCA), -2 mo (32 ± 2 wk PCA), -1.5 mo (34 ± 2 wk PCA), and -1 mo (36 ± 2 wk PCA). After hospital discharge, samples were obtained at omo (39 ± 1 wk PCA), 2 mo (48 ± 1 wk PCA), 4 mo (57 ± 1 wk PCA), 6 mo (69 ± 1 wk PCA), 9 mo (79 ± 1 wk PCA), and 12 mo (92 ± 1 wk PCA). Blood was centrifuged, and plasma was separated and stored in a nitrogen atmosphere at -70°C until analyzed for IGF-I and IGFBP-3. Statistical analyses. Data were anal yzed by the general linear model procedure of SAS version 6.0 (Cary, NC) . Each preterm infant had at least five measurements from 10 sampling ages, and term infants had at least three measurements from five sampling ages . Diet (human milk or formula) was used as a potentially influential variable in the preliminary statistical design but was removed when effects of diet were not found. The effect of gestational age at birth and time (study age) on IGF-I and IGFBP-3 was determined by a two-way repeated measures ANOVA corrected for the effect of subject by using the subject-simultaneous sums of squares as an error term. By correcting for the effect of subject, the influence of possible covariants is eliminated from the analysis. The ages included were 0, 2, 4, 6, and 12 rna when data from both term and preterm infants were available. Because blood was available at an additional number of ages in preterm compared with term infants, a repeated measures ANOVA corrected for subject effects was also performed for each gestational age group to determine the effect of study age or study age and gender on plasma IGF-I and IGFBP-3 concentrations. Fisher's LSD was used for comparisons within (study age, gender) and between (gestational age at birth) groups. Pearson 's correlation was used to determine the relationship between IGF-I and IGFBP-3 at all ages . A p value < 0.05 was considered significant in all anal yses. All analyses were completed by using software from SAS Institute, Inc. (23) . on the mainframe computer at The University of Tennessee, Memphis.
RESULTS
In term infants, there was no overall effect of study age on first year plasma IGF-I, although the plasma IGF-I concentration declined progressively from 7.6 ± 0.6 nM (59.1 ± 4.3 f.LgIL) (mean ± SE) at birth to 5.3 ± 0.4 nM (41.4 ± 3.3 f.LgIL) at 6 mo and increased again to 7.2 ± 0.6 nM (55.8 ± 4.7 f.LgIL) by 12 mo of age (Table 2) . By Fisher's LSD comparison, the IGF-I concentration at 6 mo was significantly lower than at Data shown are the least squares means:!: SE from two-way ANOVA for the effects of gestational age at birth and study age in each group. Ranges are given in parentheses. To determine IGFBP-3 in mgIL, multiply IGFBP-3 in nM by 0.0305. * Values from preterm infants were determined at these ages from expected term gestation. The complete developmental change in IGFBP-3 after preterm birth is illustrated in Fig. 2 . Within each group, ages with different letters as superscript are significantly different from one another (p < 0.05).
t Denotes a significant difference between term and preterm infants of the same age (p < 0.05). infants, there was a significant increase in IGFBP-3 from 29.2 ± 1.6 to 42.0 ± 1.3 nM (0.89 ± 0.05 to 1.28 ± 0.04 mg/L) between aand 2 mo (p < 0.01) followed by a plateau between 2 and 6 mo. From 6 to 12 mo, IGFBP-3 increased again to 70.2 nM (2.14 mg/L) (p < 0.0001). The significant increase in plasma IGFBP-3 after term birth was in contrast to the significant decrease in plasma IGF-I concentration during the same period. In preterm infants, the mean plasma IGFBP-3 concentration at enrollment (-3 mo) was 14.1 ± 3.0 nM (0.43 ± 0.09 mg/L). The concentration increased throughout the expected last intrauterine trimester and reached 29.8 ± 1.3 nM (0.91 ± 0.04 mg/L) at expected term (Fig. 2) . There was another increase in IGFBP-3 concentration between a and 2 mo (p < 0.0001) after which IGFBP-3 plateaued from 2 through 6 mo, then increased again between 6 and 12 mo (p < 0.003) (Fig. 2 , Table 3 ). IGFBP-3 was significantly higher in preterm infants compared with term infants (p < 0.05) at 2 and 4 mo and significantly lower at 12 mo (Table 3) . Age (mo) n birth (p < 0.03) and 2 mo (p < 0.05) of age ( Table 2 ). In contrast, there was a significant effect of study age on plasma IGF-I concentration in preterm infants (ANOVA, p < 0.0001).
In the preterm infants, plasma IGF-I was very low (0.75 ± 0.85 nM or 5.8 ± 6.6 J-Lg/L) at enrollment (-3 mo) and increased significantly until 2 mo corrected age (p < 0.0001) (Fig. 1) when plasma IGF-I concentration was 10.4 ± 0.7 nM or 80.8 ± 5.4 1Lg/L. The IGF-I concentration declined significantly between 2 and 9 mo (p < 0.01), then between 9 and 12 mo increased back to the high concentration seen at 2 and 4 mo (Fig. 1, Table 2 ).
There was a significant interaction between gestational age at birth and study age for IGF-I plasma concentration (p < 0.0001). As noted above, between aand 2 mo, IGF-I increased in preterm but not term infants. Preterm infants had a higher circulating IGF-I concentration than term infants at 2, 4, 6, and 12 mo corrected age (Table 2 ; p < 0.02).
There was a significant effect of study age on IGFBP-3 in both term and preterm infants (ANOVA, P < 0.0001). In term Data shown are least squares means :!: SE from two-way ANOVA for the effects of gestational age at birth and study age in each group. Ranges are given in parentheses. To determine IGF-I in fLgIL, multiply IGF-I (nM) by 7.78.
* Values from preterm infants were determined at these ages from expected term gestation. The complete developmental change in IGF-I after preterm birth is illustrated in Figure 1 . Within each group, ages with different letters as superscript are significantly different from one another (p < 0.05). t Significant differences between term and preterm infants at the same study age (p < 0.05).
584
RAJARAM ET AL. (17) also measured first year somatomedin C in longitudinal samples and found little effect of age. Two longitudinal studies with smaller numbers of infants found either no change in circulating IGF-I between birth and 3 mo (19) or a prominent early postnatal increase followed by a decrease between 2 and 6 wk of age (18) . The data presented here represent a relatively large number of term infants (n = 51) followed longitudinally during the first year of life. Our data show a progressive decline in IGF-I concentration between birth and 6 mo that reaches significance but no overall effect of time on the first-year IGF-I concentration.
DISCUSSION Table 4. Correlation of individual concentrations ofplasma IGF-I and IGFBP-3 in term infants in infancy
The pattern of IGF-I development from childhood to adult life has been more consistently established (8, 12, 26) . Although the methodologies are still evolving, the plasma IGF-I concentration typically increases with age in young children (>10.3 nM or 80 /Lg/L) with a prominent surge (>51 nM or 400 /LgIL) at puberty (20, 27) . Thereafter, plasma IGF-I declines steadily until normal adult values are reached (12, 25) . After 40 y of age, IGF-I declines again to levels lower than in early adulthood (26) .
In humans, IGF-I/somatomedin C synthesis begins as early as 9-19 wk of gestation (28). Lassarre et al. (25) showed an increase in blood IGF-I during the last intrauterine trimester in a cross-sectional study of umbilical cord samples obtained during the 20th to the 37th wk of gestation. The gradual increase in IGF-I during the interval corresponding to the last intrauterine trimester shown in our study is consistent with the above report (25) but cannot be used to infer that third trimester intrauterine and extrauterine IGF-I are the same.
There are two other longitudinal reports of circulating levels of IGF-I in preterm infants, each of relatively short duration (18, 29) . One (29) reported a decline in plasma IGF-I levels in nine sick, parenterally fed preterm infants between 6 and 28 d of age. The other (18) showed a trend for circulating levels of IGF-I to increase between birth and 6-wk adjusted age in infants born between 26 and 37 wk PCA (-3.5 and -1.5 mo). The population included infants who were appropriately grown as well as small for gestational age. The evidence thus favors a developmental increase in IGF-I expression during the last intrauterine trimester as we show here. However, although IGF-I decreased after birth in term infants, IGF-I in preterm infants increased between term and 2 mo and was remarkably higher in preterm compared with term infants at the four ages when samples from both gestational age groups were obtained: 2, 4, 6, and 12 mo ( Table 2) .
The bioavailability of circulating IGF-I to target tissues is influenced by the associated binding protein(s). IGFBP-1 and IGFBP-2 are strongly expressed in the fetus (25) Plasma IGF-I and IGFBP-3 concentrations in individual infants were significantly correlated at every age for both term (Table 4 ) and preterm (Table 5 ) infants except at -1.5 mo and -1 mo in the preterm group. IGF-I is thought to play an important role in postnatal growth. Plasma IGF-I is elevated in patients with acromegaly (6, 7) and in constitutionally tall children and adolescents (8) and is lower in pygmies (9), individuals with Laron-type dwarfism (10), intrauterine growth-retarded fetuses (11) , and children with constitutionally delayed growth (12, 13) . Declines in growth rate among children with protein energy malnutrition (14) are accompanied by lower plasma IGF-I levels, whereas subsequent refeeding reverses protein energy malnutrition, increases plasma IGF-I levels, and restores normal growth (15) .
Several groups of investigators (12, 17, 24, 25) , employing either bioassays or RIA, have shown that at term birth the cord somatomedin C IGF-I concentration is lower than normal adult values (>25.7 nM or 200 /LgIL). Our finding of a lower than normal adult (>26 nM or 200 /LgIL) concentration of IGF-I in cord blood of term infants (73.9 /LgIL) is consistent with these reports. There is disagreement, however, about the effects of postnatal age on plasma IGF-I in infancy. Tato et al. (16) and presented here are consistent with these observations in that they show an increase in IGFBP-3 during the interval corresponding to the last intrauterine trimester and much higher concentrations after expected term. Again, as noted for IGF-I, these data cannot be construed to mean that the third trimester intrauterine and extrauterine IGFBP-3 concentrations are the same.
Among infants studied at a given age, there was a highly significant positive relationship between IGF-I and IGFBP-3 in individual infants, regardless of gestational age at birth, just as in childhood and adolescence (20) . However, the developmental patterns of IGF-I and IGFBP-3 differed from each other and were further influenced by gestational age at birth. The exact role of IGFBP-3 in regulating the actions of IGF-I is not known, but IGFBP-3 is a part of the major IGF-I-binding protein complex. In normal children, it has been suggested (20, 27) that the pubertal surge in IGF-I accompanied by a less prominent increase in IGFBP-3 could favor growth. A different situation seems to exist in constitutionally tall children and adolescents who demonstrate a higher than age-appropriate IGF-I concentration but lower than age-appropriate binding protein concentration (8) . Because growth rate is higher during fetal life than in the postnatal period, a low or undetectable IGFBP-3 in the fetal tissue may have a permissive influence on the growth-promoting actions of IGF-I. Likewise, the lower IGFBP-3 reported here in male infants compared with female infants who had similar IGF-I may be related to the greater growth in male compared with female infants.
In summary, although a great deal more work will be required to understand how the relationship between IGF-I and its binding proteins influences growth, normative data on plasma IGF-I and IGFBP-3 in healthy, appropriately grown term infants are a necessary start. These normative data are contrasted here with concentrations found in healthy, normally growing preterm infants. The data demonstrate 1) that IGF-I and IGFBP-3 have different developmental patterns in the first year of life and 2) that each is influenced by gestational age at birth.
